Ovid Therapeutics (OVID) Operating Expenses (2016 - 2026)

Ovid Therapeutics' Operating Expenses history runs 11 years deep, the most recent figure standing at $17.8 million for Q1 2026.

• Quarterly Operating Expenses rose 40.74% year-over-year to $17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.9 million (down 4.7% YoY) and the FY2025 annual result came in at $49.7 million, down 20.43% from the prior year.
• Operating Expenses was $17.8 million for Q1 2026 at Ovid Therapeutics, up from $13.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $20.7 million in Q2 2024 and bottomed at $10.8 million in Q4 2024.
• A 5-year average of $14.5 million and a median of $13.4 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses tumbled 53.63% — and 2023, when it surged 50.01%.
• Ovid Therapeutics' Operating Expenses stood at $12.2 million in 2022, then jumped by 50.01% to $18.3 million in 2023, then tumbled by 41.09% to $10.8 million in 2024, then advanced by 20.49% to $13.0 million in 2025, then surged by 37.16% to $17.8 million in 2026.
• Business Quant data shows OVID's Operating Expenses at $17.8 million in Q1 2026, $13.0 million in Q4 2025, and $12.7 million in Q3 2025.